Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008099 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer
A Phase 1 study of Pancreatic Cancer, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT00008099: Completed Phase 1 study of Pancreatic Cancer, sponsored by University of Pittsburgh.
NCT00008099 is a Phase 1 study of Pancreatic Cancer that has completed, run by University of Pittsburgh. The registered enrollment target is 25 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00008099, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with resected or locally advanced unresectable pancreatic cancer.
Conditions Studied
Interventions
- BIOLOGICAL MUC1 antigen/SB AS-2
Study Locations (1)
Pennsylvania
- University of Pittsburgh Cancer Institute - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 1998-05 |
| Est. Completion | 2004-02 |
| Phase | Phase 1 |
What the finished NCT00008099 record still lists
NCT00008099 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which MUC1 antigen/SB AS-2 is the first listed.
NCT00008099 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00008099 about?
NCT00008099 is a clinical study titled "Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer". RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with resected or locally advanced unresectable pancreatic cancer.
What is the current status of trial NCT00008099?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 1998-05. Estimated completion is 2004-02.
What conditions does trial NCT00008099 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00008099?
The interventions under investigation include: MUC1 antigen/SB AS-2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00008099?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00008099 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00008099's enrollment target sits among peer trials
25 210th of 278 higher than 64 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer
RECRUITING · Phase 1
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)
RECRUITING · Phase 1
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia